查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1918128

蛋白质表现市场－2026-2031年预测

Protein Expression Market - Forecast from 2026 to 2031
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 149 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计蛋白质表现市场将从 2025 年的 37.68 亿美元成长到 2031 年的 58.52 亿美元，复合年增长率达到 7.61%。

蛋白质表现市场正经历强劲成长，这主要得益于技术创新、生物製药产业的扩张以及研发能力的提升。蛋白质表现是将遗传讯息转化为执行细胞功能的功能性蛋白质的过程，是现代生物技术和药物研发的核心技术。基因工程和蛋白质组学的进步，以及生物製药行业的蓬勃发展和对罕见疾病日益增长的关注，都在推动市场的发展。

市场主要驱动因素

基因工程的进展

基因工程技术的进步，特别是CRISPR-Cas9技术的进步，显着提升了我们设计细胞株係以提高蛋白质表现的能力。 CRISPR-Cas9基因编辑平台能够精确且有效率地编辑特定的DNA序列，简化了在不同生物体中基因的添加、删除或修饰。这些技术优势是蛋白质表现市场成长要素。

2023年1月，Kytopean公司启动了其基因递送平台Flowfect Discover的早期使用计划，旨在提高复杂基因工程材料的递送精度和效率。这正是新兴平台如何推动蛋白质表现能力提升的典型例子。此外，DNA合成技术的进步使得客製化DNA序列的建构更加便利、成本更低，从而普及了先进的基因工程工具，并扩大了蛋白质表现技术的潜在用户群。

生物製药产业的扩张

生技产业的蓬勃发展以及製药公司对生物製药的日益重视，正积极推动蛋白质表现市场的发展。包括基因工程、重组DNA技术和蛋白质表现系统在内的生物技术的快速发展，使得新型生物製药的生产成为可能。策略联盟的建立正在拓展生物製药领域，并促进蛋白质表现市场的成长。 2022年9月，CytoReason与辉瑞公司签署了一份为期五年的合作协议延期文件，旨在利用人工智慧技术进行药物发现和开发倡议。这正是伙伴关係如何加速生物製药创新以及相关蛋白质表现需求的例子。

关注罕见疾病

製药业日益重视罕见疾病孤儿药的研发，这为蛋白质表现市场创造了巨大的机会。许多孤儿药都是基于蛋白质的治疗方法，需要特定的蛋白质分子，这直接推动了对蛋白质表现技术的需求。大约有3000万美国人患有罕见疾病，这表明存在巨大的未满足医疗需求。美国国立卫生研究院（NIH）的罕见疾病临床研究网络计画等措施支持了这种对罕见疾病治疗日益增长的关注，该计画透过促进研究人员之间的合作、增加研究参与度和推动数据共用来加速医学研究。

蛋白质体学进展

蛋白质体学的进步从根本上改变了我们对蛋白质及其生物学功能的理解，并推动了蛋白质表现市场的发展。现代质谱技术，包括串联式质谱质谱和液相层析-质谱联用技术，实现了灵敏且高通量的蛋白质分析。结构测定方法，例如X射线晶体衍射、核磁共振波谱和冷冻电镜，使研究人员能够以高分辨率解析蛋白质结构，从而揭示蛋白质相互作用和机制的重要资讯。

此外，将蛋白质体学与基因组学和转录组学数据整合，能够对细胞过程进行全面分析。多体学方法提供了生物系统内基因表现调控和分子相互作用的整体情况，拓展了我们的研究能力，并催生了对先进蛋白质表现平台的需求，以支持这些整合的分析工作流程。

市场限制

儘管蛋白质表现市场成长势头强劲，但仍面临一些阻碍其扩张的挑战。蛋白质表现系统的建构和维护成本高昂，高额的初始投资可能会使小规模的研究机构和预算有限的公司难以采用这项技术。技术限制也是一大障碍：需要大量转译后修饰的真核蛋白可能无法在原核生物系统（例如细菌）中有效表达或加工，因此需要更复杂、更耗时的真核表达平台。

此外，蛋白质表现市场竞争异常激烈，许多现有企业争夺市场份额，新进入者难以立足。在这种竞争环境下，企业需要不断创新和差异化才能维持市场地位。

区域和近期趋势

由于北美拥有强大的医疗保健基础设施、不断增长的医疗保健研发投入、蛋白质技术的应用日益广泛以及慢性病负担日益加重，预计北美在预测期内将保持显着的市场份额。与其他高所得国家相比，美国的医疗保健支出仍然显着较高，无论从人均支出还是占GDP的百分比来看都是如此。不断扩张的製药业进一步推动了区域市场的成长，製药业对国民经济的贡献也显着增加。

近期市场趋势凸显了持续创新的重要性。 2023年7月，Lonza推出了TheraPRO® CHO培养基系统，该系统与GS-CHO细胞株配合使用时，可优化生产效率和蛋白质质量，从而帮助製药和生物技术公司生产治疗性蛋白质。 2023年5月，10x Genomics推出了Visium CytAssist基因和蛋白质表现分析试剂盒，扩展了其空间分析能力，并增强了其对基因和蛋白质表现模式的研究范围。

受技术进步、治疗方法创新以及生物技术和製药领域研究应用不断扩展的推动，蛋白质表现市场持续发展。

本报告的主要优势：

  • 深入分析：取得以客户群、政府政策和社会经济因素、消费者偏好、垂直产业和其他细分市场为重点的深入市场洞察，涵盖主要地区和新兴地区。
  • 竞争格局：了解主要企业采取的策略倡议，并了解透过正确的策略实现市场渗透的潜力。
  • 市场驱动因素与未来趋势：探索动态因素和关键市场趋势，以及它们将如何塑造未来的市场发展。
  • 可执行的建议：利用洞察力为策略决策提供讯息，从而在动态环境中开拓新的业务管道和收入来源。
  • 受众范围广：对新兴企业、研究机构、顾问公司、中小企业和大型企业都有益处且经济高效。

它是用来做什么的？

产业与市场洞察、商业机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法律规范及其影响、新产品开发、竞争影响

分析范围

  • 历史资料（2021-2025 年）和预测资料（2026-2031 年）
  • 成长机会、挑战、供应链前景、法规结构、客户行为和趋势分析
  • 竞争对手定位、策略和市场占有率分析
  • 按业务板块和地区（国家）分類的收入成长和预测分析
  • 公司概况（策略、产品、财务资讯、关键趋势等）

目录

第一章执行摘要

第二章市场概述

  • 市场概览
  • 市场定义
  • 分析范围
  • 市场区隔

第三章 商业情境

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 波特五力分析
  • 产业价值链分析
  • 政策和法规
  • 策略建议

第四章 技术展望

5. 按表达系统分類的蛋白质表现市场

  • 介绍
  • 原核生物
  • 哺乳动物细胞
  • 昆虫细胞
  • 酵母菌
  • 其他的

6. 按应用分類的蛋白质表现市场

  • 介绍
  • 治疗
  • 工业的
  • 用于研究

7. 按产品分類的蛋白质表现市场

  • 介绍
  • 试剂
  • 胜任细胞
  • 表达载体
  • 服务
  • 装置

8. 按地区分類的蛋白质表现市场

  • 介绍
  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 其他的
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他的
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第九章 竞争格局与分析

  • 主要企业和策略分析
  • 市占率分析
  • 企业合併、协议、商业合作
  • 竞争对手仪錶板

第十章：公司简介

  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories
  • Thermo Fisher Scientific, Inc.
  • Merck Millipore（Merck KGaA）
  • New England BioLabs, Inc.
  • Promega Corporation
  • QIAGEN
  • Takara Bio, Inc.
  • Oxford Expression Technologies
  • Lucigen Corporation

第十一章附录

  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要收益
  • 分析方法
  • 简称
简介目录
Product Code: KSI061615968

The protein expression market is expected to achieve a 7.61% CAGR, increasing from USD 3.768 billion in 2025 to USD 5.852 billion in 2031.

The protein expression market is experiencing robust growth driven by technological innovation, biopharmaceutical expansion, and evolving research capabilities. Protein expression-the process by which genetic information is converted into functional proteins that carry out cellular functions-has become central to modern biotechnology and drug development. Advancements in genetic engineering and proteomics, combined with the expanding biopharmaceutical industry and increasing focus on rare diseases, are propelling market momentum.

Core Market Drivers

Genetic Engineering Advancements

Progress in genetic engineering techniques, particularly CRISPR-Cas9 technology, has substantially enhanced the ability to engineer cell lines for improved protein expression. The CRISPR-Cas9 gene editing platform enables precise and efficient editing of specific DNA sequences, simplifying the addition, deletion, or modification of genes across diverse organisms. These technological capabilities represent major growth drivers for the protein expression market.

In January 2023, Kytopean launched an early access program for its gene delivery platform 'Flowfect Discover,' enabling delivery of complex genetic engineering materials with enhanced precision and efficiency. This exemplifies how emerging platforms are advancing protein expression capabilities. Additionally, advances in DNA synthesis technologies have made custom DNA sequence creation easier and more affordable, democratizing access to sophisticated genetic engineering tools and expanding the potential user base for protein expression technologies.

Biopharmaceutical Industry Expansion

The biotechnology industry's growth and pharmaceutical companies' increasing biologics adoption have positively contributed to protein expression market development. Rapid developments in biotechnology-including genetic engineering, recombinant DNA technology, and protein expression systems-have enabled novel biopharmaceutical production. Strategic collaborations are expanding the biopharmaceutical landscape and supporting protein expression market growth. In September 2022, CytoReason and Pfizer entered an extended five-year collaboration agreement to utilize artificial intelligence in drug discovery and development initiatives, demonstrating how partnerships are accelerating biopharmaceutical innovation and associated protein expression demands.

Rare Disease Focus

The pharmaceutical industry has emphasized orphan medication development for rare diseases, creating significant opportunities for the protein expression market. Many orphan medications are protein-based therapies requiring specialized protein molecules, directly driving demand for protein expression technologies. Approximately 30 million Americans are impacted by rare diseases, highlighting substantial unmet medical needs. The growing treatment focus is evidenced by initiatives like the NIH's Rare Diseases Clinical Research Network program, which accelerates medical research by promoting collaboration, facilitating study enrollment, and fostering data sharing among researchers.

Proteomics Advances

Progress in proteomics has fundamentally transformed understanding of proteins and their biological roles, propelling the protein expression market. Modern mass spectrometry techniques-including tandem mass spectrometry and liquid chromatography-mass spectrometry-enable sensitive, high-throughput protein analysis. Structural determination methods like X-ray crystallography, nuclear magnetic resonance spectroscopy, and cryo-electron microscopy allow researchers to determine protein structures at high resolutions, revealing critical insights into protein interactions and mechanisms.

Furthermore, integrating proteomics with genomics and transcriptomics data enables comprehensive cellular process analyses. Multi-omics approaches provide holistic views of gene expression regulation and molecular interactions within biological systems, expanding research capabilities and creating demand for sophisticated protein expression platforms that support these integrated analytical workflows.

Market Constraints

Despite positive growth trajectories, the protein expression market faces challenges impacting expansion. Establishing and maintaining protein expression systems can be expensive, with high initial investments potentially deterring smaller research organizations or budget-constrained companies from adopting these technologies. Technical limitations also present obstacles: eukaryotic proteins requiring extensive post-translational modifications may not be adequately expressed or processed in prokaryotic systems like bacteria, necessitating more complex and time-consuming eukaryotic expression platforms.

Additionally, the protein expression market experiences intense competition, with numerous established companies competing for market share, making market entry challenging for new participants. This competitive landscape requires continuous innovation and differentiation to maintain market position.

Regional Dynamics and Recent Developments

North America is expected to hold significant market share during the forecast period, supported by strong healthcare infrastructure, increasing healthcare R&D investment, growing protein technology usage, and rising chronic disease burden. Healthcare spending in the United States remains substantially higher-both per capita and as GDP percentage-compared to other high-income nations. The expanding pharmaceutical industry further augments regional market growth, with pharmaceutical sector contributions to national economies increasing significantly.

Recent market developments underscore ongoing innovation. In July 2023, Lonza launched the TheraPRO(R) CHO Media System to optimize productivity and protein quality when used with GS-CHO cell lines, supporting pharmaceutical and biotechnology companies manufacturing therapeutic proteins. In May 2023, 10x Genomics introduced the Visium CytAssist Gene and Protein Expression Assay to broaden spatial analysis capabilities, enhancing the scope of gene and protein expression pattern studies.

The protein expression market continues evolving, driven by technological sophistication, therapeutic innovation, and expanding research applications across biotechnology and pharmaceutical sectors.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2021 to 2025 & forecast data from 2026 to 2031
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information), and Key Developments among others.

Protein Expression Market Segmentation

  • By Expression System
  • Prokaryotic
  • Mammalian Cell
  • Insect Cell
  • Yeast
  • Others
  • By Application
  • Therapeutic
  • Industrial
  • Research
  • By Product
  • Reagents
  • Competent Cells
  • Expression Vectors
  • Services
  • Instruments
  • By Geography
  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. PROTEIN EXPRESSION MARKET BY EXPRESSION SYSTEM

  • 5.1. Introduction
  • 5.2. Prokaryotic
  • 5.3. Mammalian Cell
  • 5.4. Insect Cell
  • 5.5. Yeast
  • 5.6. Others

6. PROTEIN EXPRESSION MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Therapeutic
  • 6.3. Industrial
  • 6.4. Research

7. PROTEIN EXPRESSION MARKET BY PRODUCT

  • 7.1. Introduction
  • 7.2. Reagents
  • 7.3. Competent Cells
  • 7.4. Expression Vectors
  • 7.5. Services
  • 7.6. Instruments

8. PROTEIN EXPRESSION MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. USA
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. Germany
    • 8.4.2. France
    • 8.4.3. United Kingdom
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. China
    • 8.6.2. India
    • 8.6.3. Japan
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Agilent Technologies, Inc.
  • 10.2. Bio-Rad Laboratories
  • 10.3. Thermo Fisher Scientific, Inc.
  • 10.4. Merck Millipore (Merck KGaA)
  • 10.5. New England BioLabs, Inc.
  • 10.6. Promega Corporation
  • 10.7. QIAGEN
  • 10.8. Takara Bio, Inc.
  • 10.9. Oxford Expression Technologies
  • 10.10. Lucigen Corporation

11. APPENDIX

  • 11.1. Currency
  • 11.2. Assumptions
  • 11.3. Base and Forecast Years Timeline
  • 11.4. Key Benefits for the Stakeholders
  • 11.5. Research Methodology
  • 11.6. Abbreviations